PMID- 35144424
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220214
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 11
IP  - 1
DP  - 2022 Jan
TI  - The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic 
      HER2-positive breast cancer.
PG  - 332-338
LID - 10.21037/apm-21-3965 [doi]
AB  - BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast 
      cancer tends to metastasize and is associated with poor prognosis. Anti-HER2 
      treatment combined with chemotherapy or endocrine therapy is often used for 
      HER2-positive metastatic breast cancer (MBC). For later lines of therapy in 
      HER2-positive MBC, there is no standard treatment. We investigated the efficacy 
      of pyrotinib, a new irreversible tyrosine kinase inhibitor (TKI) targeting 
      epidermal growth factor receptor, HER2, and HER4, in lapatinib-resistant 
      HER2-positive MBC patients. METHODS: This is a retrospective observational study 
      including lapatinib-resistant HER2-positive MBC patients who received 
      pyrotinib-based treatment. We used the Kaplan-Meier method for the survival 
      analyses. RESULTS: A total of 31 patients were included. Concurrent treatments 
      included cytotoxic chemotherapy (29 patients, 93.6%), endocrine therapy (1 
      patient, 3.2%), and another targeted therapy (1 patient, 3.2%). The objective 
      response rate (ORR) was 25.8% and the median progression-free survival in the 
      study population was 4.5 months (95% CI: 3.1-5.9 months). The treatment-related 
      adverse events (AEs) included diarrhea, neutropenia, vomiting, fatigue, and 
      thrombocytopenia. Dose reduction to 320 mg was conducted in 19.4% of all cases 
      due to severe AEs. CONCLUSIONS: Pyrotinib-based treatment was effective and 
      generally well tolerated in lapatinib-resistant HER2-positive MBC for later line 
      treatment.
FAU - Yang, Chen
AU  - Yang C
AD  - Department of Oncology, Ruijin Hospital Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Shangguan, Chengfang
AU  - Shangguan C
AD  - Department of Oncology, Ruijin Hospital Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Lou, Guyin
AU  - Lou G
AD  - Department of Oncology, Ruijin Hospital Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Qu, Qing
AU  - Qu Q
AD  - Department of Oncology, Ruijin Hospital Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Acrylamides)
RN  - 0 (Aminoquinolines)
RN  - 0 (pyrotinib)
RN  - 0VUA21238F (Lapatinib)
SB  - IM
MH  - Acrylamides
MH  - Aminoquinolines/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - *Breast Neoplasms/drug therapy
MH  - Female
MH  - Humans
MH  - Lapatinib/therapeutic use
OTO - NOTNLM
OT  - Pyrotinib
OT  - human epidermal growth factor receptor 2-positive metastatic breast cancer 
      (HER2-positive MBC)
OT  - lapatinib
OT  - tyrosine kinase inhibitor (TKI)
EDAT- 2022/02/12 06:00
MHDA- 2022/02/15 06:00
CRDT- 2022/02/11 05:29
PHST- 2021/12/09 00:00 [received]
PHST- 2022/01/14 00:00 [accepted]
PHST- 2022/02/11 05:29 [entrez]
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
AID - 10.21037/apm-21-3965 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2022 Jan;11(1):332-338. doi: 10.21037/apm-21-3965.